Overview

A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
One-arm, multi-center clinical trial of paclitaxel (albumin-binding) combined with carboplatin for castration-resistant prostate cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel